Genetic Association Reveals Protection against Recurrence of Clostridium difficile Infection with Bezlotoxumab Treatment

Bezlotoxumab is a human monoclonal antibody against Clostridium difficile toxin B, indicated to prevent recurrence of C. difficile infection (rCDI) in high-risk adults receiving antibacterial treatment for CDI. An exploratory genome-wide association study investigated whether human genetic variation...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:mSphere
Päätekijät: Shen, Judong, Mehrotra, Devan V., Dorr, Mary Beth, Zeng, Zhen, Li, Junhua, Xu, Xun, Nickle, David, Holzinger, Emily R., Chhibber, Aparna, Wilcox, Mark H., Blanchard, Rebecca L., Shaw, Peter M.
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: American Society for Microbiology 2020
Aiheet:
Research Article
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC7203456/
https://ncbi.nlm.nih.gov/pubmed/32376702
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1128/mSphere.00232-20
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia